U.S. Markets closed

Enochian Biosciences, Inc. (ENOB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1100-0.1000 (-3.12%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0400
Open3.1000
Bid2.8600 x 1000
Ask3.4500 x 800
Day's Range2.9807 - 3.2900
52 Week Range2.6000 - 13.4300
Volume175,553
Avg. Volume293,966
Market Cap148.078M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.2350
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
    GlobeNewswire

    Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

    LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today, in the peer-reviewed American Journal of Case Reports https://www.amjcaserep.com/abstract/indexMobile/idArt/931030. A complete remission response such as this is uncommon for this highly aggressive and deadly form of brain cancer. In compliance with U.S. Food and Drug Administration guidance, SRI treated the patient with natural killer (NK) and dendritic cells (DC) from a relative who had a partial genetic mismatch. The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90 percent of glioblastomas. Enochian BioSciences acquired the intellectual property for an approach that is similar to the one used for this successful clinical outcome. The novel, proprietary strategy includes genetic modification of DCs, potentially increasing the immune response and even more effectively attacking tumors. Enochian BioSciences is actively developing this enhanced immune technology, including proof-of-concept in vivo studies of the potential to clear tumors with a focus on pancreatic cancer. In the U.S. alone, more than 60,000 persons are diagnosed with pancreatic cancer, and more than 48,000 die from the disease each year. The treatment strategy also could be applicable to several solid tumors. Dr. Anahid Jewett, a renowned tumor immunologist and cell and gene therapy investigator at UCLA who has developed a humanized mouse model of pancreatic cancer, said: “This exciting clinical finding, as well as many other directions for therapy which Enochian BioSciences is currently undertaking to develop related approaches, gives hope for the possibility of effective treatment for pancreatic cancer and other solid tumors in the future.” About Enochian BioSciences, Inc.Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. The company’s gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS, Hepatitis B, and Oncology. About Seraph Research InstituteSeraph Research Institute is a Los Angeles-based non-profit research institution, which runs basic science, translational and clinical research in pursuit of cures and effective treatments for chronic viral infections, cancers, and genetic disorders. Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: Contact: ir@enochianbio.com

  • Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
    GlobeNewswire

    Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

    LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. Executive Vice Chair Dr. Mark Dybul will provide an overview of the company’s progress, including its innovative HIV, Hepatitis B and Oncology platforms. The presentation will be available on-demand for conference attendees beginning at 7 am Eastern on Tuesday, March 9, 2021, and also will be available on the Enochian BioSciences website under the Investors/Media section in Events and Presentations. On March 10, Dr. Dybul and Chief Financial Officer Luisa Puche will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conference. More information on the conference may be found at H.C. Wainwright’s conference website. About Enochian BioSciences Inc.Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology. Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: Contact: ir@enochianbio.com

  • What You Need To Know About Enochian Biosciences, Inc.'s (NASDAQ:ENOB) Investor Composition
    Simply Wall St.

    What You Need To Know About Enochian Biosciences, Inc.'s (NASDAQ:ENOB) Investor Composition

    Every investor in Enochian Biosciences, Inc. (NASDAQ:ENOB) should be aware of the most powerful shareholder groups...